BLA 761174 · Glaxosmithkline
Jemperli
Dostarlimab-Gxly · Injection · Programmed Death Receptor-1 Blocking Antibody
NovelBreakthrough therapyAccelerated approvalPriority reviewCDER novel approval, Apr 22, 2021: To treat endometrial cancer
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
Apr 22, 2021
Approved uses
6
Original approval plus efficacy supplements
Registered trials
103
15 Phase 3, 31 recruiting
FAERS reports
2,493
2,141 serious, 296 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 19, 2026.
JEMPERLI is a programmed death receptor‑1 (PD‑1)–blocking antibody indicated: Endometrial Cancer • in combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer (EC). ( 1.1 ) • as a single agent for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced EC, as determined by an FDA‑authorized test, that has progressed on or following prior treatment with a platinum‑containing regimen in any setting and are not candidates for curative surgery or radiation. ( 1.1 , 2.1 ) Microsatellite Instability–High or Mismatch Repair Deficient Locally Advanced Rectal Cancer • as a single agent for the treatment of adult patients with Stage II/III, locally advanced rectal cancer (LARC) that is microsatellite instability‑high (MSI‑H) or dMMR, as determined by an FDA‑authorized test for solid tumors. ( 1.2 , 2.1 ) This indication is approved under accelerated approval based on sustained clinical complete response for 12 months. The long-term risk of relapse is unknown, with additional follow-up expected. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.2 ) Mismatch Repair Deficient Recurrent or Advanced Solid Tumors • as a single agent for the treatment of adult patients with dMMR recurrent or advanced solid tumors, as determined by an FDA‑authorized test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. ( 1.3 , 2.1 ) This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be...
Mechanism: Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors, and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Dostarlimab-gxly is a humanized monoclonal antibody of the IgG4 isotype that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models,...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 19, 2026 Supplement 15 · Efficacy · priority review LabelLetterMedication Guide
- Aug 1, 2024 Supplement 9 · Efficacy · priority review Label
- Jul 31, 2023 Supplement 6 · Efficacy · priority review Breakthrough therapyLabelLetterReview
- Feb 9, 2023 Supplement 4 · Efficacy LabelLetter
- Feb 9, 2023 Supplement 3 · Efficacy LabelLetter
- Apr 22, 2021 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalLabelLetterReview
1 products under this application
- JEMPERLI · DOSTARLIMAB-GXLY 500MG/10ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Dostarlimab" as an intervention, any sponsor and status, largest first.
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
Oslo University HospitalAcademic, hospital or other
NCT04817956 · 3,000 participants (planned) · Start Apr 1, 2021 · Primary completion Mar 30, 2040
Drug: Atezolizumab · For: Cancer Metastatic
Sites: Ålesund, Norway; Bergen, Norway; Bodø, Norway · 17 sites in all
- A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian CancerPivotal-lookingActive, not recruiting
Tesaro, Inc.GSK (GSK)
NCT03602859 · 1,400 participants · Start Oct 11, 2018 · Primary completion Oct 31, 2024
Drug: Niraparib; Dostarlimab (TSR-042) and 3 more · For: Ovarian Neoplasms; Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
Sites: Anchorage, Alaska; Phoenix, Arizona; Tucson, Arizona · 182 sites in all
- Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon CancerPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT05855200 · 892 participants (planned) · Start Aug 1, 2023 · Primary completion Mar 19, 2029
Drug: Dostarlimab; CAPEOX and 1 more · For: Colonic Neoplasms; Neoplasms, Colon
Sites: Tucson, Arizona; Los Angeles, California; New Haven, Connecticut · 266 sites in all
- A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell CarcinomaPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT06256588 · 864 participants (planned) · Start Mar 21, 2024 · Primary completion Jun 30, 2028
Drug: Dostarlimab; Placebo · For: Neoplasms, Head and Neck
Sites: Jonesboro, Arkansas; Los Angeles, California; Solvang, California · 277 sites in all
GlaxoSmithKlineGSK (GSK)
NCT06551142 · 845 participants (planned) · Start Sep 30, 2024 · Primary completion Oct 16, 2028
Drug: Ris-Rez; Cisplatin and 8 more · For: Neoplasms
Sites: Stanford, California; Denver, Colorado; New Haven, Connecticut · 67 sites in all
GlaxoSmithKlineGSK (GSK)
NCT02723955 · 829 participants · Start Jun 23, 2016 · Primary completion Jul 5, 2023
Drug: feladilimab (GSK3359609); GSK3174998 and 9 more · For: Neoplasms
Sites: Duarte, California; Los Angeles, California; Sarasota, Florida · 28 sites in all
- A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial CancerPivotal-lookingActive, not recruiting
Tesaro, Inc.GSK (GSK)
NCT03981796 · 785 participants · Start Jul 18, 2019 · Primary completion Nov 26, 2026
Drug: Dostarlimab; Placebo matching dostarlimab and 4 more · For: Neoplasms
Sites: Phoenix, Arizona; Scottsdale, Arizona; Tucson, Arizona · 169 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- malignant neoplasm progression254
- off label use145
- fatigue133
- rash114
- anaemia98
- arthralgia87
- diarrhoea87
- death84
- neuropathy peripheral82
- thrombocytopenia80
- nausea70
- hypothyroidism66
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 2 |
| 2019 | 9 |
| 2020 | 40 |
| 2021 | 188 |
| 2022 | 174 |
| 2023 | 171 |
| 2024 | 422 |
| 2025 | 742 |
| 2026 | 745 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Jemperli (Dostarlimab-Gxly)
2024 spending
$3.1M
Beneficiaries
48
232 claims
Per beneficiary
$65,089
$1,111.84 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $360,508 |
| 2023 | $1,596,066 |
| 2024 | $3,124,278 |
Part B: Jemperli (Dostarlimab-Gxly) · HCPCS J9272
2024 spending
$142M
Beneficiaries
1,770
9,109 claims
Per beneficiary
$80,337
2024 ASP limit $234.67 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $4,502,157 |
| 2023 | $35,992,091 |
| 2024 | $142,196,684 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
Mirza MR, Chase DM, Slomovitz BM, et al. · N Engl J Med 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Nonoperative Management of Mismatch Repair-Deficient Tumors.
Cercek A, Foote MB, Rousseau B, et al. · N Engl J Med 2025 · Clinical Trial, Phase II, Multicenter Study
- Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial.
Powell MA, Bjørge L, Willmott L, et al. · Ann Oncol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.
Cercek A, Lumish M, Sinopoli J, et al. · N Engl J Med 2022 · Clinical Trial, Phase II
- Dostarlimab and niraparib in primary advanced ovarian cancer.
Hardy-Bessard AC, Pujade-Lauraine E, Moore RG, et al. · Ann Oncol 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Systemic treatment of immune checkpoint inhibitor-induced psoriasis: Inference-based guidance.
Papp KA, Puig L, Beecker J, et al. · J Eur Acad Dermatol Venereol 2025 · Systematic Review
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.